Fast runners or long-distance champions? Rethinking AD therapy trajectories ➜ DOI: 10.1111/all.70395 A new Allergy editorial proposes an athletic metaphor for AD therapies: JAK inhibitors as “sprinters,” IL-4/IL-13 biologics as “mid-distance runners,” and emerging immune-resetting approaches as “marathoners.” An attractive framework—but perhaps the key question is not only how therapies run, but how disease evolves in each patient. As Bieber and Lauffer highlight, some patients need rapid symptom control; others long-term stability; many require both. Future AD care may rely not on a single therapeutic runner, but on strategic treatment selection and sequencing—rapid control when needed, sustained control thereafter, and perhaps eventually disease modification. Predicting disease trajectories may become as important as identifying the fastest therapy.
Bottom line: Treat the trajectory—not only the flare.
Systemic steroids in AD: old drug, unresolved questions ➜ DOI: 10.1016/j.jacig.2026.100696 In the era of expensive targeted therapies, this small placebo-controlled prednisolone study raises important questions. Oral corticosteroids rapidly improved clinical scores and broadly suppressed TH2, TH1, and TH17 pathways—but benefits faded rapidly during tapering. Despite decades of use, systemic corticosteroids in AD have never been evaluated in modern adequately powered RCTs addressing rescue treatment, rebound, safety, and longer-term disease control. Old, inexpensive therapies should not be romanticized—but neither should they escape rigorous evidence-based evaluation.
Bottom line: A common practice still carries a major evidence gap.
Beyond cytokines: when sensory neurons shape AD ➜ DOI: 10.1146/annurev-immunol-082924-065848 This Annual Review of Immunology article reminds us that itch is not simply downstream of inflammation—it is embedded in active neuroimmune circuits.
The review highlights sensory neuron populations involved in itch and pain, including IL-31 pathways, mast cell–neuropeptide interactions, and JAK1-dependent neuronal sensitization.
For AD, these concepts help explain why controlling inflammation alone may not fully control disease burden. Future care may increasingly integrate neuroimmune instability, itch–scratch amplification, sleep disruption, and patient-experienced symptoms.
Bottom line: In AD, targeting inflammation may not always be enough—sometimes we must target the itch circuitry itself.
Targeted therapy in AD: are we measuring the topical treatment gap? ➜ DOI: 10.1007/s13555-026-01771-5 This analysis of lebrikizumab trials highlights an often neglected question: what happens to topical therapy once targeted treatment starts? The encouraging message is clear: long-term lebrikizumab control was associated with remarkably low rescue topical corticosteroid use (~9–12% over maintenance and long-term extension periods). But an important gap remains across modern AD trials: topical co-therapy is poorly characterized. TCS amount, potency, proactive versus reactive use, TCI utilization, and emollient consumption are rarely captured systematically. As targeted therapies reshape AD care, standardized reporting of topical treatment patterns should become routine.
Can AD guidelines travel globally? ➜ DOI: 10.4103/ijd.ijd_421_25 New Indian AD guidelines remind us that evidence-based medicine cannot simply be exported—it must adapt. Built using GRADE methodology and Delphi consensus, these recommendations integrate efficacy, affordability, infrastructure, access, environmental exposures, and local realities. Moisturizers, topical therapy, proactive treatment, education, and implementation remain central, while biologics and JAK inhibitors are positioned within real-world access constraints. As AD care evolves globally, guidelines should ask not only what works—but what works, for whom, and under which healthcare conditions.
Bottom line: Contextual adaptation may become as important as therapeutic innovation.
